Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temanogrel - Ildong Pharmaceutical

Drug Profile

Temanogrel - Ildong Pharmaceutical

Alternative Names: APD-791; Temanogrel hydrochloride

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Ildong Pharmaceutical
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Acute coronary syndromes

Most Recent Events

  • 15 Feb 2019 Discontinued - Phase-I for Acute coronary syndromes (Combination therapy, In volunteers) in South Korea (PO) (NCT02419820)
  • 15 Feb 2019 Ildong Pharmaceutical terminates a phase I trial due to sponsor decesion for Acute coronary syndromes (Combination therapy, In volunteers) in South Korea (PO) (NCT02419820)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top